Biotechnology · Business Leader · Medicine

Carsten Thiel Tells It Like It Is On Biotechnology

 

Those who doubt the promises of biotechnology may be very disappointed when they start to see all of the amazing things that the industry is rolling out. The fact of the matter is that Carsten Thiel among others are now saying that this is the industry to keep an eye on.

 

Human Understanding Has Expanded

Human biology is an incredibly complicated topic and it is understandable that human beings did not always understand everything that goes into our own biology for a long time. That being said, the amount of knowledge that we do have about human biology has increased greatly in just the last few years even.

We now can claim a greater depth of knowledge on the topic and use that knowledge to create things that are useful. See Related Link for more information.

 

The Human Genome Has Become A Lot Cheaper To Map

The first ever human genome was completed for a price tag of billions of dollars. It was not commercially viable, and it was not something that could be done on a large-scale. Today, the cost of doing this same work is less than one-thousand dollars. That is a massive difference that has made it reasonable to ask about what else we can do in the biotechnology space as a result.

Carsten Thiel thinks that as scientists and researchers work more and more with the human genome research that we currently have that things will start to look even better for biotechnology than it already does. Carsten Thiel is willing to stake his reputation on it. Carsten Thiel has been at the heart of the biotechnology sector throughout the dawn of the current golden age because of the strong partnerships built up over the last few years.

Carsten Thiel is an expert in the world of biotechnology. The CEO of Westlake Village Biopartners believes that humanity is headed towards the Golden Age of Biotechnology.

Carsten Thiel has a Ph.D and was the CEO of Abeona Therapeutics Inc. This is a biopharmaceutical company for clinical-stages that mainly develops gene and cell therapies for genetic diseases that are rare and life-threatening. It is a company that is a major part of the golden age of biotechnology that Carsten Thiel is very much a part of.

 

Additional reference article: https://www.karyopharm.com/about/board-of-directors/